HEPA
Hepion Pharmaceuticals, Inc.
- PER (TTM)
- -
- PER (Forward)
- -0.00
- EPS (TTM)
- -
- EPS (Forward)
- -
- PBR
- 0.68
- 시가총액
- 1.66M
- 배당수익률
- -
- 베타
- 1.65
- 1개월 수익률
- 50.00%
- 3개월 수익률
- 0.00%
- 6개월 수익률
- -18.57%
- 1년 수익률
- -85.38%
- 2년 수익률
- -
- 5일 평균거래량
- 31240
- 60일 평균거래량
- 19763
- 1년 평균거래량
- 115289
- 5d/60d 거래량 비율
- 1.58×
- 60d/1y 거래량 비율
- 0.17×
- 변동성(60일, 연환산)
- 284.25%
- BB 스퀴즈 스코어
- 1.12
- SMA50 비율
- 1.14
- SMA200 비율
- 0.97
- RSI (14)
- 53
- 20일 수렴도
- 0.20
- 52주 최고
- 0.39
- 52주 최저
- 0.04
- 고점 대비
- -85.53%
- 저점 대비
- 62.86%
펀더멘털 갱신: 2026-05-10T09:21:54+00:00 · 시세 갱신: 2026-05-10T06:40:10+00:00
회사 정보
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hepatocellular carcinoma (HCC), metabolic liver diseases, and chronic liver diseases in the United States. It developed Rencofilstat, a therapeutic drug candidate that binds and inhibits the function of a specific class of isomerase enzymes called cyclophilins that regulates protein folding, as well as preclinical experiments of Rencofilstat reflects decreased liver fibrosis; liver inflammation; liver tumor burden; and titers of HBV, HCV, and HDV. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Morristown, New Jersey.